Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 19, 2012, Pages 7487-7492

  Crook, Zachary R ^a   Housman, David E ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Gene expression; Neurodegeneration; Neuroprotection; Polyglutamine; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; DOPAMINE 2 RECEPTOR; GREEN FLUORESCENT PROTEIN; HUNTINGTIN; POLYGLUTAMINE; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; EXPERIMENTAL MODEL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENETIC MODEL; GENETIC TRANSDUCTION; HUNTINGTON CHOREA; MALE; MOUSE; MOUSE STRAIN; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REPORTER GENE; WILD TYPE;

ANIMALS; BASAL GANGLIA; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; NEOSTRIATUM; NERVE TISSUE PROTEINS; NEURONS; RECEPTORS, DOPAMINE D2; RNA INTERFERENCE; TRINUCLEOTIDE REPEATS;

ANIMALIA; MURINAE; MUS;

EID: 84860812619     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1204542109     Document Type: Article

References (30)

1. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983.
2. Crook ZR, Housman DE (2011) Huntington's disease: Can mice lead the way to treatment? Neuron 69:423-435.
3. Luthi-Carter R, et al. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 9:1259-1271. (Pubitemid 30312475)
4. Kuhn A, et al. (2007) Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 16: 1845-1861. (Pubitemid 47244533)
5. Hodges A, et al. (2008) Brain gene expression correlates with changes in behavior in the R6/1 mouse model of Huntington's disease. Genes Brain Behav 7:288-299. (Pubitemid 351490234)
6. Strand AD, et al. (2007) Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci 27:11758-11768. (Pubitemid 350006916)
7. Raymond LA, et al. (2011) Pathophysiology of Huntington's disease: Time-dependent alterations in synaptic and receptor function. Neuroscience 198:252-273.
8. Andrews TC, et al. (1999) Huntington's disease progression. PET and clinical observations. Brain 122:2353-2363.
9. Glass M, Dragunow M, Faull RL (2000) The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97:505-519. (Pubitemid 30320757)
10. Cha JH, et al. (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci USA 95:6480-6485.
11. Cha JH, et al. (1999) Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos Trans R Soc Lond B Biol Sci 354:981-989.
12. Turmaine M, et al. (2000) Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci USA 97:8093-8097. (Pubitemid 30460778)
13. Hickey MA, et al. (2008) Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience 157:280-295.
14. Cyr M, Sotnikova TD, Gainetdinov RR, Caron MG (2006) Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin. FASEB J 20:2541-2543.
15. Stack EC, et al. (2007) Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. J Neurosci 27:12908-12915. (Pubitemid 350159593)
16. Gong S, et al. (2003) A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425:917-925. (Pubitemid 37376918)
17. Shuen JA, Chen M, Gloss B, Calakos N (2008) Drd1a-tdTomato BAC transgenic mice for simultaneous visualization of medium spiny neurons in the direct and indirect pathways of the basal ganglia. J Neurosci 28:2681-2685. (Pubitemid 351398859)
18. Lobo MK, Karsten SL, Gray M, Geschwind DH, Yang XW (2006) FACS-array profiling of striatal projection neuron subtypes in juvenile and adult mouse brains. Nat Neurosci 9:443-452. (Pubitemid 43290975)
19. Gerfen CR, et al. (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1429-1432. (Pubitemid 120031867)
20. Schiffmann SN, Vanderhaeghen JJ (1993) Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J Neurosci 13:1080-1087. (Pubitemid 23067595)
21. Mangiarini L, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506. (Pubitemid 26374323)
22. Li JY, Popovic N, Brundin P (2005) The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx 2: 447-464. (Pubitemid 41444878)
23. Gil JM, Rego AC (2009) The R6 lines of transgenic mice: A model for screening new therapies for Huntington's disease. Brain Res Brain Res Rev 59:410-431.
24. Carter RJ, et al. (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19:3248-3257. (Pubitemid 29174016)
25. Wheeler VC, et al. (1999) Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum Mol Genet 8(1):115-122. (Pubitemid 29039056)
26. Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet M-F (2003) Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 465(1):11-26. (Pubitemid 37075677)
27. Rising AC, et al. (2011) Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats. Exp Neurol 228(2):173-182.
28. Wheeler VC, et al. (2002) Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum Mol Genet 11: 633-640. (Pubitemid 34285134)
29. Xia H, Mao Q, Paulson HL, Davidson BL (2002) siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 20:1006-1010.
30. Gray M, et al. (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28:6182-6195.